

# Martin Bornhäuser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5227385/publications.pdf>

Version: 2024-02-01

210  
papers

11,584  
citations

50170

46  
h-index

31759

101  
g-index

214  
all docs

214  
docs citations

214  
times ranked

14138  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. <i>Blood</i> , 2002, 99, 4326-4335.	0.6	1,550
2	Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro. <i>Stem Cells</i> , 2004, 22, 377-384.	1.4	1,143
3	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	5.1	620
4	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	512
5	Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party. <i>Journal of Clinical Oncology</i> , 2007, 25, 4938-4945.	0.8	446
6	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	12.5	352
7	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	5.1	347
8	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 Internal Tandem Duplication Mutation (SORMAIN). <i>Journal of Clinical Oncology</i> , 2020, 38, 2993-3002.	0.8	335
9	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1668-1679.	5.1	250
10	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1035-1044.	5.1	237
11	Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. <i>Nature Methods</i> , 2013, 10, 788-794.	9.0	195
12	Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro. <i>Haematologica</i> , 2010, 95, 542-550.	1.7	190
13	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019, 37, 375-385.	0.8	163
14	A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. <i>Blood</i> , 2010, 116, 971-978.	0.6	157
15	Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. <i>Cytotherapy</i> , 2015, 17, 473-486.	0.3	149
16	Kit Regulates HSC Engraftment across the Human-Mouse Species Barrier. <i>Cell Stem Cell</i> , 2014, 15, 227-238.	5.2	142
17	Detection of human disease conditions by single-cell morpho-rheological phenotyping of blood. <i>ELife</i> , 2018, 7, .	2.8	125
18	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	5.8	120

#	ARTICLE	IF	CITATIONS
19	The growth and differentiation of mesenchymal stem and progenitor cells cultured on aligned collagen matrices. <i>Biomaterials</i> , 2009, 30, 5950-5958.	5.7	118
20	Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1613-1617.	1.7	98
21	Cytarabine Dose of 36 g/m <sup>2</sup> Compared With 12 g/m <sup>2</sup> Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2696-2702.	0.8	94
22	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	2.5	85
23	OXPHOS Supercomplexes as a Hallmark of the Mitochondrial Phenotype of Adipogenic Differentiated Human MSCs. <i>PLoS ONE</i> , 2012, 7, e35160.	1.1	83
24	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 279-281.	2.0	83
25	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	0.6	82
26	Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. <i>Experimental Hematology</i> , 2009, 37, 504-513.	0.2	80
27	Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. <i>Stem Cells</i> , 2016, 34, 357-366.	1.4	80
28	Gene-Expression Profiling of CD34+Hematopoietic Cells Expanded in a Collagen I Matrix. <i>Stem Cells</i> , 2006, 24, 494-500.	1.4	78
29	Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. <i>Journal of Clinical Investigation</i> , 2017, 127, 3624-3639.	3.9	78
30	Allogeneic Stem-Cell Transplantation in Patients With <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-410.	0.8	74
31	Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 462-469.	2.0	74
32	High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2102.	0.8	71
33	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. <i>Blood</i> , 2021, 137, 3145-3148.	0.6	70
34	Extracellular matrix deposition of bone marrow stroma enhanced by macromolecular crowding. <i>Biomaterials</i> , 2015, 73, 60-69.	5.7	69
35	Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Blood</i> , 2005, 106, 3314-3321.	0.6	67
36	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e161-e169.	2.2	67

#	ARTICLE	IF	CITATIONS
37	Polarization of Human Hematopoietic Progenitors During Contact with Multipotent Mesenchymal Stromal Cells: Effects on Proliferation and Clonogenicity. <i>Stem Cells and Development</i> , 2006, 15, 815-829.	1.1	66
38	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. <i>Journal of Autoimmunity</i> , 2018, 90, 116-131.	3.0	64
39	A three-dimensional <i>ex vivo</i> tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche. <i>Haematologica</i> , 2017, 102, 1215-1226.	1.7	63
40	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 123, 2960-2967.	0.6	62
41	Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers. <i>Frontiers in Immunology</i> , 2020, 11, 1338.	2.2	60
42	RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. <i>Blood</i> , 2015, 125, 3760-3768.	0.6	53
43	Polarization and Migration of Hematopoietic Stem and Progenitor Cells Rely on the RhoA/ROCK I Pathway and an Active Reorganization of the Microtubule Network. <i>Journal of Biological Chemistry</i> , 2010, 285, 31661-31671.	1.6	51
44	Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. <i>Scientific Reports</i> , 2017, 7, 42855.	1.6	51
45	Noncovalently Assembled Electroconductive Hydrogel. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 14418-14425.	4.0	50
46	Prophylactic transfer of BCR-ABL <sup>-</sup> , PR1 <sup>-</sup> , and WT1-reactive donor T cells after T cell <sup>-</sup> depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 7174-7184.	0.6	48
47	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. <i>Frontiers in Immunology</i> , 2019, 10, 1570.	2.2	48
48	Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2011, 5, 648-654.	1.3	47
49	Combined influence of biophysical and biochemical cues on maintenance and proliferation of hematopoietic stem cells. <i>Biomaterials</i> , 2017, 138, 108-117.	5.7	47
50	Endogenous bone morphogenetic proteins in human bone marrow-derived multipotent mesenchymal stromal cells. <i>European Journal of Cell Biology</i> , 2009, 88, 257-271.	1.6	46
51	Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. <i>Lancet Haematology</i> , 2018, 5, e201-e210.	2.2	44
52	Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. <i>European Journal of Haematology</i> , 2006, 76, 9-17.	1.1	43
53	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017, 8, 1844.	2.2	43
54	Mechanical phenotyping of primary human skeletal stem cells in heterogeneous populations by real-time deformability cytometry. <i>Integrative Biology (United Kingdom)</i> , 2016, 8, 616-623.	0.6	42

#	ARTICLE	IF	CITATIONS
55	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
56	Flexible Antigen-Specific Redirection of Human Regulatory T Cells Via a Novel Universal Chimeric Antigen Receptor System. <i>Blood</i> , 2014, 124, 3494-3494.	0.6	41
57	Unexpected recombinations in single chain bispecific anti-CD3 anti-CD33 antibodies can be avoided by a novel linker module. <i>Molecular Immunology</i> , 2011, 49, 474-482.	1.0	40
58	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
59	Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. <i>Blood Advances</i> , 2020, 4, 6077-6085.	2.5	40
60	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	2.5	39
61	Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. <i>British Journal of Haematology</i> , 2001, 115, 119-124.	1.2	38
62	Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e884-e891.	2.2	38
63	Retargeting of UniCAR T cells with an <i>in vivo</i> synthesized target module directed against CD19 positive tumor cells. <i>Oncotarget</i> , 2018, 9, 7487-7500.	0.8	38
64	A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells. <i>PLoS ONE</i> , 2014, 9, e93745.	1.1	37
65	Impact of CXCR4 inhibition on FLT3-ITD <sup>+</sup> positive human AML blasts. <i>Experimental Hematology</i> , 2010, 38, 180-190.	0.2	36
66	On the symmetry of siblings: automated single-cell tracking to quantify the behavior of hematopoietic stem cells in a biomimetic setup. <i>Experimental Hematology</i> , 2012, 40, 119-130.e9.	0.2	36
67	Tunneling nanotubes mediate the transfer of stem cell marker CD133 between hematopoietic progenitor cells. <i>Experimental Hematology</i> , 2016, 44, 1092-1112.e2.	0.2	36
68	A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. <i>Blood Advances</i> , 2019, 3, 1330-1346.	2.5	36
69	External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. <i>Blood</i> , 2020, 135, 1386-1395.	0.6	36
70	Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. <i>International Journal of Cancer</i> , 2015, 136, 44-54.	2.3	35
71	Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System. <i>Frontiers in Immunology</i> , 2019, 10, 38.	2.2	35
72	Dynamics of epigenetic age following hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, e321-e323.	1.7	34

#	ARTICLE	IF	CITATIONS
73	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	3.3	34
74	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
75	Expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem and progenitor cells. <i>Haematologica</i> , 2013, 98, 505-513.	1.7	32
76	Impact of Different Exercise Programs on Severe Fatigue in Patients Undergoing Anticancer Treatment—A Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 57-66.	0.6	31
77	Spheroid Culture of Mesenchymal Stromal Cells Results in Morphological Properties Appropriate for Improved Microcirculation. <i>Advanced Science</i> , 2019, 6, 1802104.	5.6	31
78	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of a Nationwide Observational Study (PROSa). <i>Cancers</i> , 2020, 12, 3590.	1.7	31
79	The prevalence of extramedullary acute myeloid leukemia detected by <sup>18</sup> F-FDG-PET/CT: final results from the prospective PETAML trial. <i>Haematologica</i> , 2020, 105, 1552-1558.	1.7	31
80	Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. <i>Leukemia</i> , 2022, 36, 111-118.	3.3	31
81	Bone marrow niche-mimetics modulate HSPC function via integrin signaling. <i>Scientific Reports</i> , 2017, 7, 2549.	1.6	30
82	Distinguishing autocrine and paracrine signals in hematopoietic stem cell culture using a biofunctional microcavity platform. <i>Scientific Reports</i> , 2016, 6, 31951.	1.6	29
83	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	1.7	29
84	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 164.	2.8	29
85	Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1401-1415.	2.0	27
86	Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 5585-5593.	3.2	26
87	Engineered Extracellular Matrices Modulate the Expression Profile and Feeder Properties of Bone Marrow-Derived Human Multipotent Mesenchymal Stromal Cells. <i>Tissue Engineering - Part A</i> , 2009, 15, 3161-3171.	1.6	26
88	Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. <i>Experimental Hematology</i> , 2013, 41, 444-461.e4.	0.2	25
89	Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2171-2177.	2.0	25
90	CD34+ -enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. <i>British Journal of Haematology</i> , 2002, 118, 1095-1103.	1.2	24

#	ARTICLE	IF	CITATIONS
91	Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 2020-2024.	3.3	23
92	Concise Review: The Bone Marrow Niche as a Target of Graft Versus Host Disease. <i>Stem Cells</i> , 2014, 32, 1420-1428.	1.4	22
93	Breast cancer cells compete with hematopoietic stem and progenitor cells for intercellular adhesion molecule 1-mediated binding to the bone marrow microenvironment. <i>Carcinogenesis</i> , 2016, 37, 759-767.	1.3	22
94	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1662-1667.	1.3	22
95	Reinforcement Learning for Precision Oncology. <i>Cancers</i> , 2021, 13, 4624.	1.7	22
96	<sup>188</sup> Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and <i>in vivo</i> T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 148, 910-917.	1.2	21
97	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. <i>Annals of Hematology</i> , 2014, 93, 279-285.	0.8	21
98	A high BMI is a risk factor in younger patients with <i>de novo</i> acute myelogenous leukemia. <i>European Journal of Haematology</i> , 2016, 97, 17-24.	1.1	21
99	Clonal hematopoiesis and its emerging effects on cellular therapies. <i>Leukemia</i> , 2021, 35, 2752-2758.	3.3	21
100	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. <i>Blood Advances</i> , 2022, 6, 1941-1946.	2.5	21
101	Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. <i>Annals of Hematology</i> , 2001, 80, 144-149.	0.8	20
102	Long-term <i>in vivo</i> imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts. <i>Scientific Reports</i> , 2020, 10, 13254.	1.6	20
103	Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. <i>Experimental Hematology</i> , 2012, 40, 934-944.	0.2	19
104	Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. <i>Onc Immunology</i> , 2015, 4, e1008342.	2.1	19
105	Human Bone Marrow Stromal Cells: A Reliable, Challenging Tool for <i>In Vitro</i> Osteogenesis and Bone Tissue Engineering Approaches. <i>Stem Cells International</i> , 2016, 2016, 1-14.	1.2	19
106	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018, 132, 818-818.	0.6	19
107	Silk Hydrogel Substrate Stress Relaxation Primes Mesenchymal Stem Cell Behavior in 2D. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 30420-30433.	4.0	18
108	Cancellous bone allograft seeded with human mesenchymal stromal cells: a potential good manufacturing practice-grade tool for the regeneration of bone defects. <i>Cytherapy</i> , 2010, 12, 658-668.	0.3	17

#	ARTICLE	IF	CITATIONS
109	T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. <i>Oncolmmunology</i> , 2019, 8, e1621676.	2.1	17
110	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	5.8	17
111	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	2.5	17
112	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	6.9	17
113	Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	15
114	Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. <i>Leukemia</i> , 2021, 35, 2936-2947.	3.3	15
115	Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 698193.	2.2	15
116	Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. <i>Cancers</i> , 2021, 13, 4785.	1.7	15
117	Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. <i>Endocrine Connections</i> , 2019, 8, 923-934.	0.8	15
118	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 4258-4266.	3.2	15
119	Phenotypic, Morphological and Adhesive Differences of Human Hematopoietic Progenitor Cells Cultured on Murine versus Human Mesenchymal Stromal Cells. <i>Scientific Reports</i> , 2015, 5, 15680.	1.6	14
120	In Vivo Chemical Screen in Zebrafish Embryos Identifies Regulators of Hematopoiesis Using a Semiautomated Imaging Assay. <i>Journal of Biomolecular Screening</i> , 2016, 21, 956-964.	2.6	14
121	Targeting Leukemia Stem Cells in the Bone Marrow Niche. <i>Biomedicines</i> , 2018, 6, 22.	1.4	14
122	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	1.7	14
123	Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 38804-38815.	0.8	14
124	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. <i>BMC Cancer</i> , 2022, 22, 201.	1.1	14
125	Biological activity of extracellular matrix-associated BMP-2. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2009, 4, 324-327.	1.3	13
126	Overexpression of Jagged-1 and Its Intracellular Domain in Human Mesenchymal Stromal Cells Differentially Affect the Interaction with Hematopoietic Stem and Progenitor Cells. <i>Stem Cells and Development</i> , 2013, 22, 2736-2750.	1.1	13



#	ARTICLE	IF	CITATIONS
127	Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells. <i>Stem Cells</i> , 2016, 34, 2224-2235.	1.4	13
128	Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 735-740.	1.2	13
129	Preclinical evaluation of platinum-loaded hydroxyapatite nanoparticles in an embryonic zebrafish xenograft model. <i>Nanoscale</i> , 2020, 12, 13582-13594.	2.8	13
130	Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1754-1760.	2.0	12
131	Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 2173-2180.	0.8	12
132	Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 35095-35106.	0.8	12
133	Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome—a pilot study. <i>Leukemia Research</i> , 2016, 47, 128-135.	0.4	11
134	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. <i>Blood Advances</i> , 2022, 6, 3294-3303.	2.5	11
135	Zebrafish In-Vivo Screening for Compounds Amplifying Hematopoietic Stem and Progenitor Cells: - Preclinical Validation in Human CD34+ Stem and Progenitor Cells. <i>Scientific Reports</i> , 2017, 7, 12084.	1.6	10
136	Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. <i>Proteomes</i> , 2018, 6, 11.	1.7	10
137	Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. <i>Bone Marrow Transplantation</i> , 2020, 55, 367-375.	1.3	10
138	Total body irradiation + fludarabine compared to busulfan + fludarabine as reduced-toxicity conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	1.3	10
139	Displaying Lipid Chains in a Peptide Polysaccharide-Based Self-Assembled Hydrogel Network. <i>Chemistry of Materials</i> , 2021, 33, 2756-2768.	3.2	10
140	Clonal Hematopoiesis in AML Patients in Hematological CR Is Present in Many Patients with Intermediate Risk AML and Is Associated with a High Prevalence of DNMT3A gene Mutations. <i>Blood</i> , 2014, 124, 121-121.	0.6	9
141	TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. <i>Oncolmmunology</i> , 2013, 2, e26770.	2.1	8
142	Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology. <i>Leukemia and Lymphoma</i> , 2017, 58, 1246-1249.	0.6	8
143	Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 691-697.	2.0	8
144	The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5584-5587.	2.5	8

#	ARTICLE	IF	CITATIONS
145	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2208-2217.	3.3	8
146	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	1.2	7
147	Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells. <i>Journal of Immunology</i> , 2019, 202, 1735-1746.	0.4	7
148	A Novel Synthetic, Xeno-Free Biomimetic Surface for Serum-Free Expansion of Human Mesenchymal Stromal Cells. <i>Advanced Biology</i> , 2020, 4, 2000008.	3.0	7
149	Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. <i>Biomarker Research</i> , 2020, 8, 20.	2.8	7
150	Cluster Randomized Trial: Sun Protection Intervention "Clever in Sun and Shade for Preschools" Effectiveness and Dissemination. <i>Children</i> , 2021, 8, 651.	0.6	7
151	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). <i>European Journal of Cancer Care</i> , 2021, 30, e13484.	0.7	7
152	Highly Sensitive Real-Time PCR of V617F-JAK2-Mutation To Monitor Minimal Residual Disease and Guide Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2006, 108, 669-669.	0.6	7
153	Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. <i>British Journal of Haematology</i> , 2019, 184, 833-836.	1.2	6
154	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients" results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	2.9	6
155	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	1.3	5
156	Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. <i>Blood Advances</i> , 2022, 6, 3684-3696.	2.5	5
157	Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 1093-1094.	1.2	4
158	Vosaroxin in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2015, 16, 1000-1001.	5.1	4
159	Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation. <i>Cytotherapy</i> , 2020, 22, 21-26.	0.3	4
160	A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial. <i>Blood</i> , 2011, 118, 497-497.	0.6	4
161	Enhancing The Efficacy and Specificity Of Antibody-Based T Cell Retargeting Strategies Against Hematological Malignancies. <i>Blood</i> , 2013, 122, 930-930.	0.6	4
162	Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML. <i>Frontiers in Oncology</i> , 2022, 12, 841608.	1.3	4

#	ARTICLE	IF	CITATIONS
163	Preventive brain radiochemotherapy alters plasticity associated metabolite profile in the hippocampus but seems to not affect spatial memory in young leukemia patients. <i>Brain and Behavior</i> , 2015, 5, e00368.	1.0	3
164	Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2016, 44, 1024-1033.e1.	0.2	3
165	UV protection for young athletes: using participatory program planning to develop a sports schools program. <i>Environmental Health and Preventive Medicine</i> , 2020, 25, 39.	1.4	3
166	Interaction of Tumor Cells with the Hematopoietic Stem and Progenitor Cell Niche. <i>Blood</i> , 2014, 124, 5139-5139.	0.6	3
167	Myelodysplastic Syndromes and Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11250.	1.8	3
168	Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 666014.	1.3	2
169	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1472-1472.	0.6	2
170	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. <i>Trials</i> , 2021, 22, 765.	0.7	2
171	An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-27.	0.6	2
172	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 811291.	1.1	2
173	Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2022, 108, 36-45.	0.2	2
174	Enumeration of WT1-specific CD8 <sup>+</sup> T cells for clinical application using an MHC <sc>S</sc>treptamer based no-wash single-platform flow cytometric assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 1001-1008.	1.1	1
175	Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies?. <i>Haematologica</i> , 2019, 104, 1101-1102.	1.7	1
176	Response to: Kobayashi et al.: Erythroblast appearance associated with natalizumab in Multiple Sclerosis and Related Disorders 2019. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 114-115.	0.9	1
177	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Blood</i> , 2011, 118, 157-157.	0.6	1
178	Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients. <i>Blood</i> , 2011, 118, 489-489.	0.6	1
179	Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis. <i>Blood</i> , 2013, 122, 489-489.	0.6	1
180	Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT). <i>Blood</i> , 2016, 128, 2304-2304.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease -. Blood, 2013, 122, 4612-4612.	0.6	1
182	Skeletal health in patients following allogeneic hematopoietic cell transplantation. Bone, 2020, , 115684.	1.4	1
183	Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia. Blood, 2021, 138, 223-223.	0.6	1
184	Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro. Blood, 2021, 138, 2596-2596.	0.6	1
185	A second infusion of CD34+ selected cells to improve poor graft function. Haematologica, 2006, 91, 870.	1.7	1
186	Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms. Frontiers in Oncology, 2021, 11, 776946.	1.3	1
187	Allogeneic Hematopoietic Cell Transplantation. Hematologic Malignancies, 2021, , 255-265.	0.2	0
188	Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution.. Blood, 2009, 114, 1203-1203.	0.6	0
189	Oxygen Tension Regulates Hematopoietic Stem Cell Migration Into An in-Vitro Niche Beneath Mesenchymal Stromal Cells.. Blood, 2009, 114, 1443-1443.	0.6	0
190	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680.	0.6	0
191	KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.. Blood, 2012, 120, 3101-3101.	0.6	0
192	Factors Influencing Peripheral Blood Progenitor Cell Yield After 2nd Mobilization With G-CSF In Allogeneic Donors. Blood, 2013, 122, 3274-3274.	0.6	0
193	TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 711-711.	0.6	0
194	Screening For Anti-Leukemic CTLs After Allogeneic Hematopoietic Stem Cell Transplantation Applying Streptamer Technology. Blood, 2013, 122, 5493-5493.	0.6	0
195	Influence Of Steroid Exposure On CMV Specific T Cells Following Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 5488-5488.	0.6	0
196	Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML " Results Of The Bridge Trial ". Blood, 2013, 122, 304-304.	0.6	0
197	Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of Tj ETQq1 1 0.784314 rgBT /Over	0.6	0
198	Azacitidine and Donor Lymphocyte Infusions As Treatment For Relapse After Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis In 115 Patients On Behalf Of The German Cooperative Transplant Study Group. Blood, 2013, 122, 4642-4642.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Differential Distribution of Clonal Hematopoiesis in Flow-Sorted Subpopulations of Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4626-4626.	0.6	0
200	Analysis of Molecular Predictors of Response to 5-Azacitine Treatment in AML and MDS Patients Preemptively Treated for Molecular Relapse of Disease. <i>Blood</i> , 2014, 124, 2384-2384.	0.6	0
201	CD97 Expression in Acute Myeloid Leukemia Is Associated with FLT3-ITD Mutation Status. <i>Blood</i> , 2014, 124, 1001-1001.	0.6	0
202	Allogeneic Stem Cell Transplantation after Conditioning with Treosulfan, Etoposide and Cyclophosphamide for Patients with Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-Containing Regimens: A Phase II-Study on Behalf of the German ALL Study Group (GMALL) and the German Cooperative Transplant Study Group. <i>Blood</i> , 2014, 124, 2461-2461.	0.6	0
203	Implementation of Diagnostic Flow Cytometry Allows for the Dissection of Age Related Loss of Y Chromosome from Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2016, 128, 5531-5531.	0.6	0
204	Flow Cytometric Response Monitoring in MDS with Del(5q) Using a Simple 5-Parameter-Score - an Elnet lmds-Flow Experience. <i>Blood</i> , 2016, 128, 3179-3179.	0.6	0
205	Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept. <i>Blood</i> , 2018, 132, 939-939.	0.6	0
206	Myelodysplastic Syndromes and Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, .	1.8	0
207	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
208	<i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
209	Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse. <i>Cancer Management and Research</i> , 2022, Volume 14, 547-559.	0.9	0
210	Predicting unplanned hospital readmission in palliative outpatients (PRePP) – study protocol of a longitudinal, prospective study to identify informal caregiver-related and structural predictors. <i>BMC Palliative Care</i> , 2022, 21, 62.	0.8	0